Chief Executive Officer

Transcript : Dyne Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 09

Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer

Certain Common Stock of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-AUG-2025.

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Director, Managed Markets Liaison

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The Director, Managed Markets Liaison will engage with healthcare decision-makers to provide scientific and clinical support while advancing patient outcomes and medication access within national and regional payer accounts.

Sign up with Google

Sign in with Google